Pipeline image

L606: A next-generation inhaled treprostinil

Developed in partnership with Pharmosa Biopharm, L606 (liposomal treprostinil inhalation suspension) is an investigational sustained-release liposomal formulation of treprostinil that has the potential to improve the delivery of treprostinil to the lung for patients living with PAH and PH-ILD.

Potential benefits include:

  • Less frequent dosing (2x daily)
  • Sustained drug exposure over 24 hours
  • Improved tolerability with lower peak exposures and fewer systemic and inhalation-related issues
  • Rapid nebulization with a hand-held portable system

L606 is delivered via rapid nebulization with a hand-held portable system and may offer therapeutic benefits for patients with PAH and PH-ILD.

L606 is composed of treprostinil encapsulated within liposomes (110 – 140 nm) in a sodium citrate-bicarbonate buffer. In this formulation, drug release is controlled by local levels of bicarbonate in the lung to extend apparent half-life.

Diagram of a liposome. It shows a circular lipid membrane encapsulating an internal aqueous space with treprostinil molecules inside.

Modeled plasma concentration following administration of TYVASO® or L6061

Line graph comparing mean plasma concentration of treprostinil over 24 hours for two treatments: Tyvaso (54 µg QID) and L606 (102 µg BID). Tyvaso shows higher peak concentrations with sharper declines, while L606 shows lower, more sustained levels. The graph also indicates waking and sleeping hours.

† Tyvaso data over 4 hours are from the comparative bioavailability study, and the remaining data are simulated to show Tyvaso 24-hour exposure.

‡ L606 data over 12 hours are from the comparative bioavailability study, and the remaining data are simulated to show L606 24-hour exposure.

TYVASO is a registered trademark of United Therapeutics Corporation.

Clinical trials

Learn more about our clinical trials focusing on the study of inhaled therapies for the treatment of PAH and PH-ILD.

See our clinical trials

Commercial products

 

YUTREPIA™ (treprostinil) inhalation powder

YUTREPIA is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Delivered through a convenient, low-resistance, palm-sized device, YUTREPIA was designed using Liquidia’s PRINT® technology. PRINT enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation.

EXPLORE YUTREPIA (TREPROSTINIL) INHALATION POWDER


See Prescribing Information

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact Liquidia Technologies, Inc. at 1-888-393-LQDA (5732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

YUTREPIA PRINT particles

  • 1.3 μm in size
  • Precisely engineered particles
  • Trefoil shape

Treprostinil Injection

Liquidia promotes the appropriate use of Sandoz® Treprostinil Injection in the United States in conjunction with its commercial partner, Sandoz, Inc. (Sandoz), which holds the Abbreviated New Drug Application (ANDA) with the FDA.

Treprostinil Injection is a fully substitutable AP-rated generic formulation of Remodulin® (treprostinil) Injection. Treprostinil Injection is therapeutically equivalent to Remodulin.

Remodulin® is a registered trademark of United Therapeutics Corporation.

Explore Treprostinil injection


See Prescribing Information

Report an Adverse Event

Pioneers in rare cardiopulmonary disease

Explore the science behind our clinical trials.

See our publications

References:

  1. Tully, J., Saggar, R., Prabel, J., Garcia, A., Patel, S., Chen, K., Kan, P. Clinical Pharmacokinetics of an Extended-Release Formulation of Inhaled Liposomal Treprostinil (L606) to Reduce Dosing Frequency. Poster presented at: Pulmonary Vascular Research Institute 2024 Annual Congress; February 2, 2024; London, England